These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 25155625)

  • 21. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
    Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
    Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
    Emanuele S; Lauricella M; Carlisi D; Vassallo B; D'Anneo A; Di Fazio P; Vento R; Tesoriere G
    Apoptosis; 2007 Jul; 12(7):1327-38. PubMed ID: 17351739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus nuclear antigen 3A promotes cellular proliferation by repression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1.
    Tursiella ML; Bowman ER; Wanzeck KC; Throm RE; Liao J; Zhu J; Sample CE
    PLoS Pathog; 2014 Oct; 10(10):e1004415. PubMed ID: 25275486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Counteracting survival functions of EBNA3C in Epstein-Barr virus (EBV)-driven lymphoproliferative diseases by combination of SAHA and bortezomib.
    Hui KF; Yeung PL; Tam KP; Chiang AKS
    Oncotarget; 2018 May; 9(38):25101-25114. PubMed ID: 29861856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
    Hui KF; Chiang AK
    Int J Cancer; 2010 May; 126(10):2479-89. PubMed ID: 19816947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
    Huang H; Liu N; Yang C; Liao S; Guo H; Zhao K; Li X; Liu S; Guan L; Liu C; Xu L; Zhang C; Song W; Li B; Tang P; Dou QP; Liu J
    PLoS One; 2012; 7(12):e52576. PubMed ID: 23285100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
    Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
    Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
    Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
    Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
    Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.
    Shirley CM; Chen J; Shamay M; Li H; Zahnow CA; Hayward SD; Ambinder RF
    Blood; 2011 Jun; 117(23):6297-303. PubMed ID: 21447826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature.
    Kelly GL; Stylianou J; Rasaiyaah J; Wei W; Thomas W; Croom-Carter D; Kohler C; Spang R; Woodman C; Kellam P; Rickinson AB; Bell AI
    J Virol; 2013 Mar; 87(5):2882-94. PubMed ID: 23269792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphomas differ in their dependence on Epstein-Barr virus.
    Vereide DT; Sugden B
    Blood; 2011 Feb; 117(6):1977-85. PubMed ID: 21088132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.
    Hutchings IA; Tierney RJ; Kelly GL; Stylianou J; Rickinson AB; Bell AI
    J Virol; 2006 Nov; 80(21):10700-11. PubMed ID: 16920819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
    Perez-Chacon G; de Los Rios C; Zapata JM
    Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
    Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
    Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Li C; Li R; Grandis JR; Johnson DE
    Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib.
    Hui KF; Yeung PL; Chiang AK
    Oncotarget; 2016 Jan; 7(4):4454-67. PubMed ID: 26683357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells].
    Jiang XX; Zhang QL; Chen XY; Wu WL; Shen ZX; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1215-9. PubMed ID: 19840453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.